In 2018, based upon the results of NCT01945775, Talazoparib (Talzenna, Pfizer Inc.)was FDA approved for BRCA mutated, HER2 negative, advanced breast cancer [2, 19]. This evidence concerns the gene ERBB2 and breast carcinoma.